Astellas To Do Phase II Test Of Transplant Drug Of Alavita Of U.S.
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma is to conduct Phase IIb trials on a transplant-rejection drug for U.S.-based Alavita Pharmaceuticals under a contract the two signed